Skip to Content

Nora M. Navone, MD, PhD

Present Title & Affiliation

Primary Appointment

Professor, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

My research laboratory focuses mainly on the pathogenesis of prostate cancer bone metastases. Prostate cancer has clinical features unique among adult solid tumors, including high tropism for bone and the osteoblastic nature of most bone metastases. Yet little is known about the dynamic prostate cancer–bone cell interactions essential to growth of metastatic cells in bone. We investigate the nature of prostate cancer cell – osteoblast interactions and their exacerbation of tumor progression in bone. Focusing on tumor–bone interactions, not on biologic changes in tumor cells alone as most "standard" studies do, is a unique aspect of my research program.

Lack of clinically relevant models of prostate cancer has substantially limited this type of study. We thus developed such models and use them to enhance our understanding of molecular interactions required in metastasis.

Fibroblast growth factor 9 (FGF9) and FGF receptor 1 (FGFR1) are likely mediators of prostate cancer growth in bone; we confirmed their aberrant expression in human prostate cancer. We are now studying the molecular mechanism underlying FGF-mediated prostate cancer growth in bone and whether prostate cancer cells activate classic FGFR downstream target genes (e.g., FRS2alpha/MAPK) in bone. These studies use the in vitro and in vivo models we developed.

Prostate cancer cells induce osteoblast proliferation and differentiation. Specifically, prostate cancer cells activate the Wnt canonical pathway and induce expression of the transcription factor Runx2 in osteoblasts. These findings suggest that prostate cancer cells induce new bone formation by activating true bone-development programs in osteoblasts.

Education & Training

Degree-Granting Education

1989 University of Buenos Aires, School of Medicine, Buenos Aires, Argentina, PHD, Biomedical Sciences
1988 University of Buenos Aires, School of Sciences, Buenos Aires, Argentina, MS, Computer Science
1981 University of Buenos Aires, School of Medicine, Buenos Aires, Argentina, MD, Medicine


Academic Appointments

Member, Graduate Faculty, Texas A&M Health Science Center, Houston, TX, 7/2014
Associate Professor, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2003-8/2015
Member, The University of Texas Health Science Center Graduate School of Biomedical Sciences (GSBS), Houston, TX, 1996-present
Assistant Professor of Medicine/Assistant Cell Biologist, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/1995-8/2003
Assistant Professor, Department of Epigenetics and Molecular Carcinogenesis, Science Park-Research Division, The University of Texas M. D. Anderson Cancer Center, Smithville, TX, 1994-1995
Assistant Professional, Porphyrins and Porphyrias Research Center, National Research Council (CONICET), Buenos Aires, Argentina, 1982-1989

Administrative Appointments/Responsibilities

Director, Bone Histomorphometry Core Laboratory, The Bone Disease Program of Texas, Baylor College of Medicine-MD Anderson Cancer Center, Houston, TX, 2007-present
Director, Prostate Cancer Patient-Derived Xenografts Facility, (formerly "Tissue Culture Core Facility of the Prostate Cancer Research Program"), David H. Koch Center for Applied Research in Genitourinary Cancers, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1996-present

Institutional Committee Activities

Reviewer, Office of Research Administration Institutional Research Grant (IRG) Program, 2014-present
Reviewer, Global Academic Programs (GAP) Sister Institution Network Funds (SINF), 2014-present
Committee Member, Oversight Committee for The Molecular Cytogenetics Core Facility, 2008-present

Honors and Awards

2013 Waun Ki Hong Award for Excellence in Team Science - Transdisciplinary Prostate Research Team, MD Anderson Cancer Center

Professional Memberships

American Association for Cancer Research (AACR)
Member, 1994-present
The Bone Disease Program of Texas, Baylor College of Medicine - MD Anderson Cancer Center, Houston, TX
Member, 2002-present
The University of Texas Graduate School of Biomedical Sciences, Houston, TX
Faculty, 1996-present
The University of Texas MD Anderson Cancer Center Metastasis Research Center (MRC), Houston, TX
Member, 2010-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee WK, Dias-Neto E, Pasqualini R, Arap W. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A. e-Pub 6/2015. PMCID: PMC4500257.
2. Pasqualini R, Millikan RE, Christianson DR, Cardó-Vila M, Driessen WH, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do KA, Navone NM, Efstathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W. Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study. Cancer. e-Pub 4/2015. PMCID: PMC25832466.
3. Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, Sidman RL, Pasqualini R, Arap W. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci U S A 112(12):3776-81, 3/2015. e-Pub 3/2015. PMCID: PMC4378428.
4. Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia 29(2):515, 2/2015. PMID: 25651464.
5. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. (Research highlights on this article published in Nature Reviews Urology on September 23, 2014 and Cancer Discovery on September 25, 2014.). Sci Transl Med 6(252):252ra122, 9/2014. PMCID: PMC4407499.
6. Fong EL, Martinez M, Yang J, Mikos AG, Navone NM, Harrington DA, Farach-Carson MC. Hydrogel-based 3d model of patient-derived prostate xenograft tumors suitable for drug screening. Mol Pharm 11(7):2040-50, 7/7/2014. e-Pub 4/29/2014. PMCID: PMC4096229.
7. Gueron G, Giudice J, Valacco P, Paez A, Elguero B, Toscani M, Jaworski F, Leskow FC, Cotignola J, Marti M, Binaghi M, Navone N, Vazquez E. Heme-oxygenase-1 implications in cell morphology and the adhesive behavior of prostate cancer cells. Oncotarget 5(12):4087-102, 6/30/2014. PMCID: PMC4147308.
8. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting Poly(ADP-Ribose) Polymerase and the c-Myb-Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer. Sci Signal 7(326):ra47, 5/20/2014. e-Pub 5/20/2014. PMCID: PMC4135429.
9. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 74(6):1651-60, 3/15/2014. e-Pub 1/28/2014. PMCID: PMC4009928.
10. Corn PG, Wang F, McKeehan WL, Navone N. Targeting Fibroblast Growth Factor Pathways in Prostate Cancer. Clin Cancer Res 19(21):5856-66, 11/2013. e-Pub 9/2013. PMCID: PMC3926427.
11. Cotignola J, Leonardi DB, Shahabi A, Acuna AD, Stern MC, Navone N, Scorticati C, DeSiervi A, Mazza O, Vazquez E. Glutathione-S-gtransferase (GST) polymorphisms are associated with relapse after radical prostatectomy. Prostate Cancer Prostatic Dis 16(1):28-34, 3/2013. e-Pub 11/2012. PMCID: PMC3626169.
12. Ferrando M, Wan X, Meiss R, Yang J, De Siervi A, Navone N, Vazquez E. Heme Oxygenase-1 (HO-1) Expression in Prostate Cancer Cells Modulataes the Oxidative Response in Bone Cells. PLoS One 8(11):e80315, e80315. doi: 10.1371/journal.pone.0080315., 2013. e-Pub 11/2013. PMCID: PMC3817116.
13. Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate 72(15):1638-47, 11/2012. e-Pub 3/2012. PMID: 22457212.
14. Elguero B, Gueron G, Giudice J, Toscani MA, De Luca P, Zalazar F, Coluccio-Leskow F, Meiss R, Navone N, De Siervi A, Vazquez E. Unveiling the association of STAT3 and HO-1 in prostate cancer: Role beyond heme degradation. Neoplasia 14(11):1043-56, 11/2012. PMCID: PMC3514752.
15. Yang P, Cartwright CA, Li J, Wen S, Prokhorova IN, Shureiqi I, Troncoso P, Navone NM, Newman RA, Kim J. Arachidonic acid metabolism in human prostate cancer. Int J Oncol 41(4):1495-503, 10/2012. e-Pub 8/2012. PMCID: PMC3982713.
16. Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia 26(9):2114-23, 9/2012. e-Pub 3/2012. PMCID: PMC3381862.
17. Dafni H, Burghardt AJ, Majumdar S, Navone NM, Ronen SM. Vascular patterning and permeability in prostate cancer models with differing osteogenic properties. NMR Biomed 25(6):843-51, 6/2012. e-Pub 12/2011. PMID: 22134886.
18. Wan X, Li ZG, Yingling JM, Yang J, Starbuck MW, Ravoori MK, Kundra V, Vazquez E, Navone NM. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth. Bone 50(3):695-703, 3/2012. e-Pub 12/2011. PMCID: PMC3278589.
19. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W. Integrative Molecular Profiling Reveals Asparagine Synthetase Is a Target in Castration-Resistant Prostate Cancer. Am J Pathol 180(3):895-903, 3/2012. e-Pub 1/2012. PMID: 22245216.
20. Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM. Activation of β-Catenin Signaling in Androgen Receptor-Negative Prostate Cancer Cells. Clin Cancer Res 18(3):726-36., 2/2012. PMCID: PMC3271798.
21. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling Lethal Prostate Cancer Variant with Small Cell Carcinoma Features. Clin Cancer Res 18(3):666-77, 2/2012. e-Pub 12/2011. PMCID: PMC3923417.
22. Sircar K, Huang H, Hu L, Liu Y, Dhillon J, Cogdell D, Aprikian A, Efstathiou E, Navone N, Troncoso P, Zhang W. Mitosis phase enrichment with identification of mitotic centromere-associated Kinesin as a therapeutic target in castration-resistant prostate cancer. PLoS One 7(2):e31259, 2012. e-Pub 2/2012. PMCID: PMC3281954.
23. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3(111):111ra121, 11/2011. PMCID: PMC3476478.
24. Ferrando M, Gueron G, Elguero B, Giudice J, Salles A, Leskow FC, Jares-Erijman EA, Colombo L, Meiss R, Navone NM, De Siervi A, Vazquez E. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Angiogenesis. e-Pub 8/2011. PMCID: PMC3817116.
25. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: Morphological, immunohistochemical, and gene expression profiles. Prostate 71(8):846-56, 6/2011. e-Pub 11/2010. PMCID: PMC3883511.
26. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM. Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene fusion Positive Prostate Cancer. Cancer Cell 19(5):664-78, 5/2011. PMCID: PMC3113473.
27. Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone NM. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clin Cancer Res 17(8):2328-38, 4/2011. e-Pub 2/2011. PMCID: PMC3078947.
28. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 42(1):11-7, 1/2011. e-Pub 10/2010. NIHMSID: NIHMSNIHMS613007.
29. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J. Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One 6(12):e28840, 2011. e-Pub 12/2011. PMCID: PMC3237548.
30. Prantl L, Muehlberg F, Navone NM, Song YH, Vykoukal J, Logothetis CJ, Alt EU. Adipose tissue-derived stem cells promote prostate tumor growth. Prostate 70(15):1709-15, 11/2010. e-Pub 6/2010. PMID: 20564322.
31. Lee YC, Cheng CJ, Huang M, Bilen MA, Ye X, Navone NM, Chu K, Kao HH, Yu-Lee LY, Wang Z, Lin SH. Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol 221(1):68-76, 5/2010. e-Pub 1/2010. PMCID: PMC2936767.
32. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ. Prioritizing genes associated with prostate cancer development. BMC Cancer 10(1):599, 2010. e-Pub 11/2010. PMCID: PMC2988752.
33. Ravoori M, Czaplinska AJ, Sikes C, Han L, Johnson EM, Qiao W, Ng C, Cody DD, Murphy WA, Do KA, Navone NM, Kundra V. Quantification of mineralized bone response to prostate cancer by noninvasive in vivo μCT and non-destructive ex vivo μCT and DXA. PLoS One 5(3):e9854, 2010. e-Pub 3/2010. PMCID: PMC2847943.
34. Gueron G, De Siervi A, Ferrando M, Salierno M, De Luca P, Elguero B, Meiss R, Navone N, Vazquez ES. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. Mol Cancer Res 7(11):1745-55, 11/2009. e-Pub 11/2009. PMID: 19903769.
35. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDA ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27(39):5195-203, 9/2008. PMCID: PMC2562662.
36. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis through FGF9-mediated mechanisms. J Clin Invest 118(8):2697-710, 8/2008. PMCID: PMC2447924.
37. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res 14(12):3729-36, 6/2008. PMCID: PMC2562877.
38. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM. Low density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27(5):596-603, 1/2008. PMID: 17700537.
39. Sacca P, Meiss R, Casas G. Mazza O, Calvo JC, Navone NM, Vazquez E. Nuclear translocation of heme oxygenase-1 is associated to prostate cancer. Br J Cancer 97(12):1683-89, 12/2007. PMCID: PMC2360287.
40. Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res 67(14):6544-8, 7/2007. PMCID: PMC2000837.
41. Cheng CJ, Ye XC, Vakar-Lopez F, Kim J, Tu SM, Chen DT, Navone NM, Yu-Lee LY, Lin SH, Hu MC. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res 5(7):675-84, 7/2007. PMCID: PMC2000833.
42. Kundra V, Ng CS, Ma J, Bankson JA, Price RE, Cody DD, Do KA, Han L, Navone NM. In vivo imaging of prostate cancer involving bone in a mouse model. Prostate 67(1):50-60, 1/2007. PMID: 17031813.
43. Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG. Inhibition of bone remodeling and prostate skeletal metastases by the vascular targeting agent VEGF121/rGel. Cancer Res 66(22):10919-28, 11/2006. PMID: 17108129.
44. Peleg S, Khan F, Navone NM, Cody DD, Johnson EM, Van Pelt CS, Posner GH. Inhibition of prostate cancer-meditated osteoblastic bone lesions by the low-calcemic analog 1alpha-hydroxymethyl-16-ene-26,27-bishomo-25-hydroxy vitamin D3. J Steroid Biochem Mol Biol 97(1-2):203-11, 10/2005. e-Pub 8/2005. PMID: 16081281.
45. Fizazi K, Navone NM. [Preclinical models of prostate cancer]. Bull Cancer 92(2):129-41, 2/2005. PMID: 15749642.
46. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res 24(5A):2897-2903, Sep-Oct, 9/2004. PMID: 15517894.
47. Navone NM, Olive M, Troncoso P. Isolation and culture of prostate cancer cell lines. Methods Mol Med 88:121-32, 2004. PMID: 14634223.
48. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9(7):2587-97, 7/2003. PMID: 12855635.
49. Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas Mdel C, Olive M, Hsieh JT, Logothetis CJ, Navone NM. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 23(8):1289-96, 8/2002. PMID: 12151346.
50. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 99(12):7866-71, 6/2002. PMCID: PMC122986.
51. Vidanes GM, Paton V, Wallen E, Peehl DM, Navone N, Brooks JD. Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells. Prostate 51(4):225-30, 6/2002. PMID: 11987150.
52. Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone NM, Hsieh JT. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem 277(5):12622-31, 4/2002. e-Pub 1/2002. PMID: 11812785.
53. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordoñez NG, Troncoso P, Navone NM. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 8(3):775-781, 3/2002. PMID: 11895908.
54. Plonowski A, Schally AV, Nagy A, Groot K, Krupa M, Navone NM, Logothetis C. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett 176(1):57-63, 2/2002. PMID: 11790454.
55. Newman RA, Yang J, Raymond M, Finlay V, Cabral F, Vourloumis D, Stephens LC, Troncoso P, Wu X, Logothetis CJ, Nicolaou KC, Navone NM. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother Pharmacol 48(4):319-26, 10/2001. PMID: 11710633.
56. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 61(14):5652-59, 7/2001. PMID: 11454720.
57. Zhao XY, Peehl DM, Navone NM, Feldman D. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141(7):2548-56, 7/2000. PMID: 10875257.
58. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6:703-706, 6/2000. PMID: 10835690.
59. Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res 6(3):1190-97, 3/2000. PMID: 10741751.
60. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 162(6):2192-99, 12/1999. PMID: 10569618.
61. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 161:304-308, 1999. PMID: 10037428.
62. Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von Eschenbach AC, Pathak S. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. Cancer Genet Cytogenet 106(2):105-109, 10/1998. PMID: 9797773.
63. Pisters LL Troncoso P, Navone NM. Prolonged survival with metastatic prostate cancer to bone. J Urol 159:2100, 6/1998. PMID: 9598540.
64. Rajagopal S, Navone NM, Troncoso P, Fritsche HA, Chakrabarty S. Modulation of cellular proliferation and production of prostate-specific antigen and matrix adhesion molecules in human prostate carcinoma cells by polypeptide growth factors: comparative analyses of MDA PCa2a with established cell lines. Int J Oncol 12(3):589-595, 3/1998. PMID: 9472097.
65. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3(12):2493-500, 12/1997. PMID: 9815652.
66. Polo CF, Buzaleh AM, Vazquez ES, Afonso SG, Navone NM, Battle AM. Griseofulvin-induced hepatopathy due to abnormalities in heme pathway. Gen Pharm 29:207-210, 8/1997. PMID: 9251900.
67. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ. Expression of Bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157:569-574, 2/1997. PMID: 8996359.
68. Polo CF, Afonso SG, Navone NM, Rossetti MV, Battle AM. Zinc aminolevulinic acid dehydratase reactivation index as a tool for diagnosis of lead exposure. Ecotox and Environ Safety 32:267-272, 12/1995. PMID: 8964254.
69. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, Chung LW. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 45:470-475, 3/1995. PMID: 7879337.
70. Chen Y, Navone NM, Conti CJ. Expression of cyclin D1 in human prostate cancer cell lines. Urol Oncol 1:101-108, 1995.
71. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1669, 10/1993. PMID: 7692074.
72. Navone NM, Vazquez ES, Polo CF, Batlle AM. Rhodanese and ALA-S in mammary tumor and liver from normal and tumor-bearing mice. Comp Biochem Physiol 102B(1):83-5, 5/1992. PMID: 1526138.
73. Navone NM, Afonso SG, Polo CF, Batlle AM. Uroporphyrinogen decarboxylase from mouse mammary carcinoma and liver of normal and tumor-bearing mouse. Comp Biochem Physiol 102(1):87-92, 5/1992. PMID: 1526139.
74. Navone NM, Bianchi AB, Angel JM, Conti CJ. A novel polymorphism near the mouse Int-2 locus. Mamm Genome 3:296-297, 1992. PMID: 1638089.
75. Conti CJ, Bianchi AB, Navone NM, Ruggieri BA, Caamano J, Goodrow T, Klein-Szanto AJ. Tumor suppressor genes in squamous cell carcinoma. Prog Clin Biol Res 376:85-101, 1992. PMID: 1528931.
76. Bianchi AB, Navone NM, Conti CJ. Detection of loss of heterozygosity in formalin-fixed paraffin-embedded tumor specimens by the polymerase chain reaction. Am J Pathol 138:279-84, 2/1991. PMID: 1992758.
77. Navone NM, Polo CF, Frisardi AL, Battle AM. Mouse mammary carcinoma porphobilinogenase and hydroxymethylbilane synthetase. Comp Biochem Physiol 98:67-71, 1991. PMID: 2060282.
78. Bianchi AB, Navone NM, Conti CJ. Overlapping loss of heterozygosity by mitotic recombination on mouse chromosome 7F1-ter in skin carcinogenesis. Proc Natl Acad Sci USA 88:7590-7594, 1991.
79. Navone NM, Buzaleh AM, Polo CF, Afonso SG, Vazquez ES, Batlle AM. The effect of griseofulvin on the heme pathway--II. An exhaustive analysis during short and long-term challenge. Gen Pharmacol 22:1179-83, 1991. PMID: 1810812.
80. Navone NM, Polo CF, Frisardi AL, Andrade NE, Battle AM. Heme biosynthesis in human breast cancer. Mimetic "in vitro" studies and some heme enzymatic activity levels. Int J Biochem 22:1407-11, 1990. PMID: 2276414.
81. Navone NM, Polo CF, Dinger RM, Battle AM. Heme regulation in mouse mammary carcinoma and liver of tumor bearing mice I. Effect of allyl-isopropylacetamide and veronal on delta-aminolevulinate synthetase, cytochrome P-450 and cytochrome oxidase. Int J Biochem 22(9):1005-8, 1990. PMID: 2178097.
82. Afonso SG, Polo CF, Navone NM, Vazquez ES, Buzaleh AM, Schoua E, Battle AM. In vivo prevention and reversal by the antimitotic colchicine and other related compounds of some porphyrinogenic drug action on heme pathway. Gen Pharmacol 21:423-6, 1990. PMID: 2379798.
83. Navone NM, Polo CF, Frisardi AL, Battle AM. Mouse mammary carcinoma alpha-aminolevulinate dehydratase. Comp Biochem Physiol 96:729-31, 1990. PMID: 2225774.
84. Polo CF, Navone NM, Cirigliano A, Garro J, Rossetti MV, Wider EA. Un metodo para la medicion de la actividad de Uroporfirinogeno Decarboxilasa. Acta BioqClin Latinoamer XXIII:183-185, 1990.
85. Polo CF, Navone NM, Afonso SG, Buzaleh AM, Schoua E, Vazquez ES, Batlle A. Allyl-isopropyl-acetamide and glycerine reproduce in mice clinical and biochemical manifestations of acute intermittent porphyria. Med Sci Res 15:1335-6, 1988.
86. Polo CF, Navone NM, Afonso SG, Buzaleh AM, Schoua E, Battle AM. Planificacion de los estudios bioquimicos para un laboratorio de porfiria. . Acta Bioq Clin Latinoamer XXII 543:559, 1988.
87. Navone NM, Frisardi EL, Resnik A, Battle AM, Polo CF. Porphyrin biosynthesis in human breast cancer. Preliminary mimetic “in vitro” studies. Med Sci Res 16:61-62, 1988.
88. Vazquez E, Afonso SG, Buzaleh AM, Navone NM, Polo CF, Schoua E, Battle AM. The effect of griseofulvin on the heme pathway. Studies on tissue explants cultures. Toxicology 46(1):73-82, 10/1987. PMID: 3660422.
89. Afonso SG, Buzaleh AM, Navone NM, Polo CF, Schoua E, Vazques E, Battle AM. Acerca de la fototoxicaidad de la griseofulvina. possibles mecanismos de accion empleando cultivos de explantes tisulares. Rev. Arg Dermatol 68:303-10, 1987.
90. Vazquez E, Navone NM, Polo CF, Afonso SG, Buzaleh AM, Battle AM. Biosintesis de porfirinas en cultivo de explantes tisulares. condiciones optimas. Rev Arg Dermatol 68:121-29, 1987.
91. Soto I, Navone NM, Rossetti MV, Vaquero N, Batlle A. Lepra y porfiria cutanea tarta. primer caso de coexistencia. Rev Arg Dermatol 68:107-13, 1987.
92. Vazquez E, Buzaleh AM, Navone NM, Polo CF, Schoua E, Afonso SG, Battle AM. Cultivo de explantes tisulares II: grado de lisis y su proteccion por el acido-amino -aminoolevulico. Ann Med Intern (Madrid) 3:258-62, 1986.
93. Parera VE, Afonso SG, Navone NM, Stella AM, Battle AM, Aguilar P, Mendez L, Castagno J, Gianantonio CA. Porfiria variegata en una nina de 4 anos. Rev Arg Dermat 67:129-31, 1986.

Invited Articles

1. Navone NM. P-TEFb joins the family of cdks in oncology, promotes cell growth of cancer cells. Cell Cycle 9(15):2933-35, 8/2010. e-Pub 8/2010. PMID: 20703082.
2. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL. The current state of preclinical prostate cancer animal models. Prostate 68(6):629-39, 5/2008. PMID: 18213636.
3. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res 14(6):1599-602, 3/2008. PMID: 18347159.
4. Logothetis C, Tu SM, Navone NM. Targeting prostate cancer bone metastases. Cancer 97(3 Suppl):785-8, 2/2003. PMID: 12548576.
5. Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev 17(4):361-31, 1998. PMID: 10453280.

Book Chapters

1. Navone NM, Olive M, Troncoso P. The isolation and culture of prostate cancer cell lines. In: Cancer Cell Culture-Methods and Protocols. 88. Ed(s) Simon Langdon Ed. Humana Press: Totowa, NJ, 121-132, 2004.
2. McDonnell, TJ, Bruckheimer EM, Gjerston BT, Honda T, Navone NM. The molecular regulation and therapeutic implications of cell death in prostate cancer. In: Cancer Chemotherapy and Apoptosis. Humana Press, 241-225, 1999.

Grant & Contract Support

Title: Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer
Funding Source: DOD - PCRP Synergistic Idea Development Award
Role: Principal Investigator
Duration: 9/22/2014 - 9/21/2017
Title: FGFR Inhibitors in Prostate Cancer Bone Metastasis
Funding Source: Janssen Pharmaceutical Companies of Johnson & Johnson
Role: Principal Investigator
Duration: 8/14/2014 - 7/31/2017
Title: Development of Prostate Cancer Xenografts to Model Human Prostate Cancer
Funding Source: Prostate Cancer Foundation Movember Action Plan Initiative
Role: Principal Investigator
Duration: 1/1/2014 - 12/31/2015
Title: Determining the Aggressiveness of Prostate Cancer using Vivo-Hyerpolarized Metabolic Imaging
Funding Source: MD Anderson Institutional Research Grant
Role: Collaborator
Principal Investigator: Niki Zacharias
Duration: 12/1/2013 - 12/31/2014
Title: Modeling Prostate Cancer Bone Metastasis in the Mouse-basic Biology and Translational Impact
Funding Source: MD Anderson Cancer Center Sister Institution Network Fund (SINF) - German Cancer Research Center National Center for Tumor Diseases
Role: Principal Investigator
Duration: 11/1/2013 - 3/14/2016
Title: The Prostate Cancer Patient Derived Xenograft Program
Funding Source: MD Anderson Prostate Cancer Research Program (PCRP)
Role: Principal Investigator
Duration: 10/7/2013 - 10/6/2014
Title: Flagship Project 3: Establish Concepts for Advancement of Biomarker-driven Clinical Trials for Treatment-Refractory Prostate Cancer
Funding Source: MDA Prostate Cancer Moonshot
Role: Principal Investigator
Duration: 9/20/2012 - 8/30/2015
Title: Role of HO-1 nuclear localization in prostate cancer: a function beyond heme degradation
Funding Source: National Agency of Research and Development of Argentina (CONCyt) Scientific and Technologic Projects (PICT) with Collaborating Scientist from Foreign Institution
Role: Other Significant Contributor
Principal Investigator: Elba Vasquez
Duration: 9/2/2011 - 9/1/2014
Title: Activation of Prostate Cancer Stem Cells Through Aberrant FGF Signaling
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Principal Investigator
Principal Investigator: Fen Wang
Duration: 7/1/2011 - 6/30/2013
Title: Early Passage Prostate Cancer Xenografts to Test Drug Efficacy in Castrate-Resistant Prostate Cancer
Funding Source: AstraZeneca
Role: Principal Investigator
Duration: 9/1/2010 - 8/31/2012
Title: Generation of a Novel Therapeutic Prostate Cancer
Funding Source: Cisthera, Inc.
Role: Collaborator
Principal Investigator: Staunton
Duration: 6/1/2010 - 5/31/2011
Title: Building on FGFR inhibition to develop effective combination therapies
Funding Source: Prostate Cancer Foundation
Role: Principal Investigator
Duration: 3/15/2010 - 3/14/2012
Title: Project 4: Targeting FGF Signaling in Prostate Cancer Progression
Funding Source: MD Anderson Cancer Center Prostate Spore
Role: Leader, Project 4
Principal Investigator: Logothetis
Duration: 9/2/2009 - 8/31/2014
Title: Characterization of Gene Expression Patterns of Microenvironment in Metastasized Osteoblastic Prostate Cancer
Funding Source: Department of Defense (DOD)
Role: Co-Principal Investigator
Duration: 5/12/2008 - 6/11/2012
Title: Beta-catenin/TCF Pathway and Castrate Resistant Progression of Osteoblastic Bone Metastases
Funding Source: Department of Defense (DOD)
Role: Principal Investigator
Duration: 5/12/2008 - 5/11/2012
Title: Role of HO1 y VEGF in Prostate Cancer Bone Metastases
Funding Source: National Agency of Research and Development of Argentina-(CONCyt)-Scientific and Technologic Projects (PICT) with Collaborating Scientist from Foreign Institutions
Role: Co-Investigator
Duration: 3/1/2008 - 2/28/2011
Title: Characterization of WWOX, the Cancer Gene Spanning FRA16D
Funding Source: NIH/NCI
Role: Other Significant Contributor
Principal Investigator: C. Marcelo Aldaz
Duration: 9/1/2003 - 5/31/2015

Last updated: 11/18/2015